Literature DB >> 31322822

Emerging roles of exosomal miRNAs in breast cancer drug resistance.

Hamid Najminejad1, Seyed Mehdi Kalantar2, Meghdad Abdollahpour-Alitappeh3, Mohammad Hossein Karimi4, Alexander M Seifalian5, Mazaher Gholipourmalekabadi6,7, Mohammad Hasan Sheikhha2.   

Abstract

Breast cancer (BC), as a heterogeneous disease, is considered as one of the most common malignancies in women worldwide. The resistance of BC cells to therapeutic agents has remained a big challenge in the treatment of BC patients. Some factors such as cytokines, exosomes, and soluble receptors were recognized as crucial agents involved in the development of drug resistance. However, the exact mechanisms underlying the drug resistance is still unknown. There is growing evidence to support the emerging roles of exosomes, especially exosomal miRNAs, in tumor initiation, angiogenesis, proliferation, migration, invasion, metastasis, and drug resistance. Therefore, identification of BC-specific exosomal miRNAs and their underlying mechanisms would be helpful to define sensitivity to therapeutic drugs and establish an appropriate therapeutic strategy. This review focuses mainly on the roles of exosomal miRNAs and their associated mechanisms in the resistance of BC cells to therapeutic agents, as well as critically examines the potential of these macromolecules as a treatment biomarker in BC patients.
© 2019 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  breast cancer; drug resistance; exosomal miRNA; exosomes; microRNA; therapeutics

Mesh:

Substances:

Year:  2019        PMID: 31322822     DOI: 10.1002/iub.2116

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  8 in total

Review 1.  Gastrointestinal cancer drug resistance: the role of exosomal miRNAs.

Authors:  Mahsa Salehi; Asma Vafadar; Seyyed Hossein Khatami; Mortaza Taheri-Anganeh; Omid Vakili; Amir Savardashtaki; Babak Negahdari; Parisa Naeli; Hamid Behrouj; Hassan Ghasemi; Ahmad Movahedpour
Journal:  Mol Biol Rep       Date:  2021-11-30       Impact factor: 2.316

2.  Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer.

Authors:  Zhi-Jun Zhang; Xing-Guo Song; Li Xie; Kang-Yu Wang; You-Yong Tang; Miao- Yu; Xiao-Dong Feng; Xian-Rang Song
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-02

3.  Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1.

Authors:  Xiaoping Pan; Xiaolv Hong; Jinguo Lai; Lu Cheng; Yandong Cheng; Mingmei Yao; Rong Wang; Na Hu
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

Review 4.  How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects.

Authors:  Sylwia Tabor; Małgorzata Szostakowska-Rodzos; Anna Fabisiewicz; Ewa A Grzybowska
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 5.  Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.

Authors:  Amal Qattan
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

6.  Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.

Authors:  Amal Qattan; Taher Al-Tweigeri; Wafa Alkhayal; Kausar Suleman; Asma Tulbah; Suad Amer
Journal:  Genes (Basel)       Date:  2021-04-09       Impact factor: 4.096

7.  microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: A case-control study.

Authors:  Alfiah Amiruddin; Muhammad Nassrum Massi; Andi Asadul Islam; Ilhamjaya Patellongi; Muhammad Yogi Pratama; Noorwati Sutandyo; Rosdiana Natzir; Mochammad Hatta; Nani Harlina Md Latar; Syarifuddin Wahid
Journal:  Ann Med Surg (Lond)       Date:  2021-11-22

Review 8.  Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors.

Authors:  Pierre Autin; Christophe Blanquart; Delphine Fradin
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.